126 related articles for article (PubMed ID: 29287771)
1. Lower antibody functionality in middle-aged adults compared to adolescents after primary meningococcal vaccination: Role of IgM.
van der Heiden M; van Ravenhorst MB; Bogaard M; Boots AMH; Berbers GAM; Buisman AM
Exp Gerontol; 2018 May; 105():101-108. PubMed ID: 29287771
[TBL] [Abstract][Full Text] [Related]
2. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
[TBL] [Abstract][Full Text] [Related]
4. Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults.
van der Heiden M; Boots AMH; Bonacic Marinovic AA; de Rond LGH; van Maurik M; Tcherniaeva I; Berbers GAM; Buisman AM
Front Immunol; 2017; 8():817. PubMed ID: 28769927
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
6. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
BMC Med Res Methodol; 2019 Jan; 19(1):1. PubMed ID: 30611213
[TBL] [Abstract][Full Text] [Related]
7. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
[TBL] [Abstract][Full Text] [Related]
10. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
[TBL] [Abstract][Full Text] [Related]
11. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.
Idoko OT; Okolo SN; Plikaytis B; Akinsola A; Viviani S; Borrow R; Carlone G; Findlow H; Elie C; Kulkarni PS; Preziosi MP; Ota M; Kampmann B
Vaccine; 2014 Jul; 32(33):4220-7. PubMed ID: 24863486
[TBL] [Abstract][Full Text] [Related]
12. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
[TBL] [Abstract][Full Text] [Related]
13. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.
Quiambao BP; Bavdekar A; Dubey AP; Jain H; Kolhe D; Bianco V; Miller JM; Van der Wielen M
Hum Vaccin Immunother; 2017 Mar; 13(3):636-644. PubMed ID: 28152332
[TBL] [Abstract][Full Text] [Related]
14. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants.
Poellabauer EM; Pavlova BG; Fritsch S; Singer J; Neubauer C; Doralt J; Valenta-Singer B; Ehrlich HJ
Vaccine; 2013 Aug; 31(35):3611-6. PubMed ID: 23672977
[TBL] [Abstract][Full Text] [Related]
15. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
Borrow R; Andrews N; Goldblatt D; Miller E
Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
[TBL] [Abstract][Full Text] [Related]
16. Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.
Broderick MP; Romero-Steiner S; Rajam G; Johnson SE; Milton A; Kim E; Choi LJ; Radin JM; Schmidt DS; Carlone GM; Messonnier N; Faix DJ
Clin Vaccine Immunol; 2016 Aug; 23(8):672-80. PubMed ID: 27280619
[TBL] [Abstract][Full Text] [Related]
17. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
[TBL] [Abstract][Full Text] [Related]
20. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
